Aug 14, 2019
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
Jun 19, 2019
Global HIV Disease Coverage Forecast and Market 2019-2024: B/F/TAF will Drive Significant Revenue Growth Due to its Attractive Combination of an INSTI and a Preferred Backbone
May 14, 2019
Hilliard & Shadowen, LLP Report Coalition Of Consumers, Activists, And Payors Sues Gilead And Other Manufacturers For Anticompetitive Practices On HIV Medicines
Apr 30, 2019
Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement
Apr 19, 2019
Mass Tort Alleges Gilead Sciences, Inc. Withheld Safer Drugs From HIV/AIDS Patients, Manipulated Patent Timing for Profit, Announces Jenner Law
Oct 03, 2018
Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)
Jul 24, 2018
Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA(TM) (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario
Jul 17, 2018
Janssen Announces U.S. FDA Approval of SYMTUZA(TM) (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Feb 20, 2018
Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
Oct 25, 2017
Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial
Oct 04, 2017
The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir
Sep 25, 2017
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1